← Back
Data updated: Mar 10, 2026
IPCA LABS LTD
CardiovascularNeurologyImmunology
IPCA LABS LTD is a generic drug manufacturer focused on Cardiovascular, Neurology, Immunology.
2006
Since
28
Drugs
-
Trials
634
Approved (2yr)
Key Drugs
No active drugs
Recent Activity
BUPROPION HYDROCHLORIDE 2026-02-25
Labeling
GABAPENTIN 2026-02-24
Labeling
GABAPENTIN 2026-02-18
Labeling
LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE 2026-02-17
Labeling
GABAPENTIN 2026-02-17
Labeling
GABAPENTIN 2026-02-17
Labeling
TRAMADOL HYDROCHLORIDE 2026-02-13
Labeling
TRAMADOL HYDROCHLORIDE 2026-02-13
Labeling
GABAPENTIN 2026-02-12
Labeling
TRAMADOL HYDROCHLORIDE 2026-02-12
Manufacturing (CMC)
SEC Filings
Pro
Loading...
Therapeutic Focus
Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5
Cardiovascular 56%
5 drugs
Neurology 22%
2 drugs
Immunology 11%
1 drugs
Gastroenterology 11%
1 drugs
Pipeline Strength Pro
Loading...
Competitors Pro
Bristol-Myers Squibb big-pharma
Immunology, Gastroenterology, Neurology
BAUSCH specialty
Immunology, Cardiovascular, Gastroenterology
Takeda big-pharma
Immunology, Gastroenterology, Neurology
Pfizer big-pharma
Immunology, Gastroenterology
PAI HOLDINGS PHARM big-pharma
Neurology, Cardiovascular, Immunology
Active (13)
Discontinued (15)
Company Info
- First Approval
- 2006-09-18
- Latest
- 2026-02-24
- Applications
- 32
FDA Sponsor Names
IPCA LABS LTDIPCA LABS